A handful of other trials evaluated whether patients with HER2+ breast cancer receive greater benefit from dose intense anthracyclines, defined as either a higher cumulative dose or more frequent dosing in the curative setting (Table 3). This evidence concerns the gene ERBB2 and breast carcinoma.